According to the latest report by IMARC Group, titled, “Anticoagulants Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026“, the global anticoagulants market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 10% during 2021-2026.

Blood clots form when blood thickens, forming a semi-solid mass in any part of the body. This can lead to severe health issues, such as heart attack, stroke, pulmonary embolism, transient ischemic attacks, deep vein thrombosis (DVT), etc. Owing to this, doctors prescribe anticoagulant drugs to people who are at a high risk of blood clot formation. These drugs aid in thinning blood, reducing or preventing blood clotting, and prolonging the clotting period. They are generally available in capsule or tablet form, including rivaroxaban, warfarin, dabigatran, apixaban, etc.

Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/anticoagulants-market/requestsample

Market Trends

The sudden outbreak of the COVID-19 pandemic is leading to an increasing number of individuals becoming afflicted by hypercoagulability, which is becoming one of the biggest causes of mortality across the globe. This is catalyzing the demand for anticoagulant drugs to treat this thrombotic condition in critically ill or hospitalized patients. Moreover, the rising incidences of risk factors, such as trauma, extended sitting, smoking, blood disorders, autoimmune diseases, etc., that can cause blood clotting in various body parts are also augmenting the global market. Additionally, the growing prevalence of the human immunodeficiency virus (HIV), hepatitis C, Lyme disease, obesity, cancer, chronic inflammation, etc., is further propelling the market growth. Besides this, the improving diagnosis rates and the escalating need for target therapeutics are expected to fuel the anticoagulants market over the forecasted period.

NoteWe are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

  • Alexion Pharmaceuticals Inc
  • Aspen Holdings
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company Limited
  • Reddy’s Laboratories Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson Private Limited
  • Pfizer Inc.

The report has segmented the market based on drug class, route of administration, distribution channel and application.

Breakup by Drug Class:

  • Novel Oral Anticoagulants (NOACs)
  • Heparin and Low Molecular Weight Heparin (LMWH)
  • Vitamin K Antagonist
  • Others

Breakup by Route of Administration:

  • Oral Anticoagulant
  • Injectable Anticoagulant

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Others

Breakup by Application:

  • Atrial Fibrillation and Heart Attack
  • Stroke
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Others

Breakup by Region:

  • North America
  • Asia-Pacific
  • Europe
  • Latin America
  • Middle East and Africa

Table of Content:

1    Preface
2    Scope and Methodology

2.1    Objectives of the Study
2.2    Stakeholders
2.3    Data Sources
2.3.1    Primary Sources
2.3.2    Secondary Sources
2.4    Market Estimation
2.4.1    Bottom-Up Approach
2.4.2    Top-Down Approach
2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

4.1    Overview
4.2    Key Industry Trends
5    Global Anticoagulants Market
5.1    Market Overview
5.2    Market Performance
5.3    Impact of COVID-19
5.4    Market Forecast
6    Market Breakup by Drug Class
6.1    Novel Oral Anticoagulants (NOACs)
6.1.1 Market Trends
6.1.2 Market Forecast
6.2    Heparin and Low Molecular Weight Heparin (LMWH)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3    Vitamin K Antagonist
6.3.1 Market Trends
6.3.2 Market Forecast
6.4    Others
6.4.1 Market Trends
6.4.2 Market Forecast
7    Market Breakup by Route of Administration
7.1    Oral Anticoagulant
7.1.1 Market Trends
7.1.2 Market Forecast
7.2    Injectable Anticoagulant
7.2.1 Market Trends
7.2.2 Market Forecast
8    Market Breakup by Distribution Channel
8.1    Hospital Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2    Retail Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3    Online Stores
8.3.1 Market Trends
8.3.2 Market Forecast
8.4    Others
8.4.1 Market Trends
8.4.2 Market Forecast
9    Market Breakup by Application
9.1    Atrial Fibrillation and Heart Attack
9.1.1 Market Trends
9.1.2 Market Forecast
9.2    Stroke
9.2.1 Market Trends
9.2.2 Market Forecast
9.3    Deep Vein Thrombosis (DVT)
9.3.1 Market Trends
9.3.2 Market Forecast
9.4    Pulmonary Embolism (PE)
9.4.1 Market Trends
9.4.2 Market Forecast
9.5    Others
9.5.1 Market Trends
9.5.2 Market Forecast
10    Market Breakup by Region
10.1    North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2    Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3    Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4    Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5    Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11    SWOT Analysis
11.1    Overview
11.2    Strengths
11.3    Weaknesses
11.4    Opportunities
11.5    Threats
12    Value Chain Analysis
13    Porters Five Forces Analysis

13.1    Overview
13.2    Bargaining Power of Buyers
13.3    Bargaining Power of Suppliers
13.4    Degree of Competition
13.5    Threat of New Entrants
13.6    Threat of Substitutes
14    Price Analysis
15    Competitive Landscape

15.1    Market Structure
15.2    Key Players
15.3    Profiles of Key Players
15.3.1    Alexion Pharmaceuticals Inc
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2    Aspen Holdings
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3    Bayer AG
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4    Boehringer Ingelheim International GmbH
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.5    Bristol-Myers Squibb Company
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6    Daiichi Sankyo Company Limited
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7    Dr. Reddy’s Laboratories Ltd
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8    GlaxoSmithKline plc
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9    Johnson & Johnson Private Limited
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10    Pfizer Inc.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11    Sanofi
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact us:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Website: https://www.imarcgroup.com
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800

LEAVE A REPLY

Please enter your comment!
Please enter your name here